Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease

The Lancet · 1982 · vol. 319(8278) , pp. 928–930 · doi:10.1016/s0140-6736(82)91932-8 · PMID:6122770 · W1982193610
RCT OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-21 ⓘ

This controlled trial investigated the efficacy of the antigonadotropin danazol in treating painful nodular benign breast disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.

My notes (saved in your browser only)

MeSH descriptors

Breast Diseases Danazol Gonadotropins Pain Pregnadienes Adult Breast Diseases Clinical Trials as Topic Danazol Danazol Danazol Dose-Response Relationship, Drug Double-Blind Method Female Gonadotropins Humans Pain Pregnadienes Random Allocation

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (17)

Cited by (18)

Source provenance

openalex
last seen: 2026-05-10T10:18:44.795447+00:00
pubmed
last seen: 2026-10-08T21:58:02.984372+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK